These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine. Maasumi K; Michael RL; Rapoport AM Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205 [TBL] [Abstract][Full Text] [Related]
3. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Chiang CC; Schwedt TJ Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505 [TBL] [Abstract][Full Text] [Related]
4. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. Cohen F; Yuan H; Silberstein SD BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313 [TBL] [Abstract][Full Text] [Related]
6. New drugs targeting calcitonin gene-related peptide for the management of migraines. Tana C; Cipollone F; Giamberardino MA; Martelletti P Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401 [TBL] [Abstract][Full Text] [Related]
7. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants. Do TP; Al-Saoudi A; Ashina M Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458 [TBL] [Abstract][Full Text] [Related]
9. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Charles A; Pozo-Rosich P Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411 [TBL] [Abstract][Full Text] [Related]
10. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047 [TBL] [Abstract][Full Text] [Related]
12. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A; Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028 [TBL] [Abstract][Full Text] [Related]
13. Novel Medications for the Treatment of Migraine. Ceriani CEJ; Wilhour DA; Silberstein SD Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638 [TBL] [Abstract][Full Text] [Related]
14. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Yuan H; Spare NM; Silberstein SD Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020 [TBL] [Abstract][Full Text] [Related]